BRAF and Familial prostate cancer: In our study, we describe two mCRPC patients with tumors harboring a p.K601E BRAF mutation with early disease progression after commencing enzalutamide treatment, indicating potential relevance of these mutations in driving prostate cancer cell growth and enzalutamide resistance.